Sucampo Pharmaceuticals (NASDAQ: SCMP) is one of 288 publicly-traded companies in the “Bio Therapeutic Drugs” industry, but how does it weigh in compared to its rivals? We will compare Sucampo Pharmaceuticals to related businesses based on the strength of its valuation, dividends, profitability, risk, analyst recommendations, earnings and institutional ownership.

Profitability

This table compares Sucampo Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Sucampo Pharmaceuticals -61.99% 56.58% 15.47%
Sucampo Pharmaceuticals Competitors -4,766.74% -354.83% -43.39%

Valuation & Earnings

This table compares Sucampo Pharmaceuticals and its rivals gross revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Sucampo Pharmaceuticals $247.08 million $107.68 million -3.68
Sucampo Pharmaceuticals Competitors $464.68 million $167.54 million -6.72

Sucampo Pharmaceuticals’ rivals have higher revenue and earnings than Sucampo Pharmaceuticals. Sucampo Pharmaceuticals is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Insider & Institutional Ownership

55.4% of Sucampo Pharmaceuticals shares are owned by institutional investors. Comparatively, 51.7% of shares of all “Bio Therapeutic Drugs” companies are owned by institutional investors. 4.1% of Sucampo Pharmaceuticals shares are owned by insiders. Comparatively, 16.9% of shares of all “Bio Therapeutic Drugs” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk and Volatility

Sucampo Pharmaceuticals has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Comparatively, Sucampo Pharmaceuticals’ rivals have a beta of 6.57, suggesting that their average stock price is 557% more volatile than the S&P 500.

Analyst Ratings

This is a summary of recent recommendations for Sucampo Pharmaceuticals and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sucampo Pharmaceuticals 0 1 5 0 2.83
Sucampo Pharmaceuticals Competitors 1379 4471 12299 312 2.63

Sucampo Pharmaceuticals currently has a consensus price target of $18.00, suggesting a potential upside of 48.76%. As a group, “Bio Therapeutic Drugs” companies have a potential upside of 33.53%. Given Sucampo Pharmaceuticals’ stronger consensus rating and higher probable upside, research analysts clearly believe Sucampo Pharmaceuticals is more favorable than its rivals.

Summary

Sucampo Pharmaceuticals beats its rivals on 8 of the 13 factors compared.

Sucampo Pharmaceuticals Company Profile

Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).

Receive News & Ratings for Sucampo Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sucampo Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.